The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells

References

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11 - 30; http://dx.doi.org/10.3322/caac.21166; PMID: 23335087
   PubMed Web of Science ®Google Scholar
• Freitas D, Fernandes GdosS, Hoff PM, Cunha JE. Medical management of pancreatic adenocarcinoma. Pancreatology 2009; 9:223 - 32; http://dx.doi.org/10.1159/000199433; PMID: 19420981
   PubMed Web of Science ®Google Scholar
• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010; 7:163 - 72; http://dx.doi.org/10.1038/nrclinonc.2009.236; PMID: 20101258
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267 - 77; http://dx.doi.org/10.1001/jama.297.3.267; PMID: 17227978
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403 - 13; PMID: 9196156
   PubMed Web of Science ®Google Scholar
• Long J, Zhang Y, Yu X, Yang J, LeBrun DG, Chen C, Yao Q, Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin Ther Targets 2011; 15:817 - 28; http://dx.doi.org/10.1517/14728222.2011.566216; PMID: 21391891
   PubMed Web of Science ®Google Scholar
• Dobbelstein M, Moll UM. Targeting Tumor-Supportive Cellular Machineries in Anticancer Drug Development. Nat Rev Drug Discov In press
   Web of Science ®Google Scholar
• Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, Kiefer JA, Henderson MC, Trent JM, Von Hoff DD, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009; 7:43; http://dx.doi.org/10.1186/1479-5876-7-43; PMID: 19519883
   PubMed Web of Science ®Google Scholar
• Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ, Denny WA, Canman CE, Kraker AJ, Lawrence TS, et al. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 2009; 8:45 - 54; http://dx.doi.org/10.1158/1535-7163.MCT-08-0662; PMID: 19139112
   PubMed Web of Science ®Google Scholar
• Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, et al. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 2011; 17:3706 - 15; http://dx.doi.org/10.1158/1078-0432.CCR-10-3082; PMID: 21482692
   PubMed Web of Science ®Google Scholar
• Köpper F, Bierwirth C, Schön M, Kunze M, Elvers I, Kranz D, Saini P, Menon MB, Walter D, Sørensen CS, et al. Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity. Proc Natl Acad Sci U S A 2013; 110:16856 - 61; http://dx.doi.org/10.1073/pnas.1304355110; PMID: 24082115
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MA, Wang X, Linding R, Ong SE, Weaver D, Carr SA, et al. DNA damage activates a spatially distinct late cytoplasmic cell-cycle checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell 2010; 40:34 - 49; http://dx.doi.org/10.1016/j.molcel.2010.09.018; PMID: 20932473
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr Opin Cell Biol 2009; 21:245 - 55; http://dx.doi.org/10.1016/j.ceb.2009.01.018; PMID: 19230643
   PubMed Web of Science ®Google Scholar
• Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 2007; 11:175 - 89; http://dx.doi.org/10.1016/j.ccr.2006.11.024; PMID: 17292828
   PubMed Web of Science ®Google Scholar
• Fryer RA, Barlett B, Galustian C, Dalgleish AG. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide. Anticancer Res 2011; 31:3747 - 56; PMID: 22110196
   PubMed Web of Science ®Google Scholar
• Akada M, Crnogorac-Jurcevic T, Lattimore S, Mahon P, Lopes R, Sunamura M, Matsuno S, Lemoine NR. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res 2005; 11:3094 - 101; http://dx.doi.org/10.1158/1078-0432.CCR-04-1785; PMID: 15837765
   PubMed Web of Science ®Google Scholar
• Anderson DR, Meyers MJ, Vernier WF, Mahoney MW, Kurumbail RG, Caspers N, Poda GI, Schindler JF, Reitz DB, Mourey RJ. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007; 50:2647 - 54; http://dx.doi.org/10.1021/jm0611004; PMID: 17480064
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003; 3:421 - 9; http://dx.doi.org/10.1016/S1535-6108(03)00110-7; PMID: 12781359
   PubMed Web of Science ®Google Scholar
• Feijoo C, Hall-Jackson C, Wu R, Jenkins D, Leitch J, Gilbert DM, Smythe C. Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing. J Cell Biol 2001; 154:913 - 23; http://dx.doi.org/10.1083/jcb.200104099; PMID: 11535615
   PubMed Web of Science ®Google Scholar
• Petermann E, Maya-Mendoza A, Zachos G, Gillespie DA, Jackson DA, Caldecott KW. Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 2006; 26:3319 - 26; http://dx.doi.org/10.1128/MCB.26.8.3319-3326.2006; PMID: 16581803
   PubMed Web of Science ®Google Scholar
• Xiao Z, Xue J, Sowin TJ, Rosenberg SH, Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005; 24:1403 - 11; http://dx.doi.org/10.1038/sj.onc.1208309; PMID: 15608676
   PubMed Web of Science ®Google Scholar
• Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends Mol Med 2011; 17:88 - 96; http://dx.doi.org/10.1016/j.molmed.2010.10.009; PMID: 21087899
   PubMed Web of Science ®Google Scholar
• Carrassa L, Damia G. Unleashing Chk1 in cancer therapy. Cell Cycle 2011; 10:2121 - 8; http://dx.doi.org/10.4161/cc.10.13.16398; PMID: 21610326
   PubMed Web of Science ®Google Scholar
• Jackson JR, Gilmartin A, Imburgia C, Winkler JD, Marshall LA, Roshak A. An indolocarbazole inhibitor of human checkpoint kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res 2000; 60:566 - 72; PMID: 10676638
   PubMed Web of Science ®Google Scholar
• Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 2013; 5:868 - 77; http://dx.doi.org/10.1016/j.celrep.2013.10.025; PMID: 24239348
   PubMed Web of Science ®Google Scholar
• Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307 - 20; http://dx.doi.org/10.1038/nrd1691; PMID: 15789122
   PubMed Web of Science ®Google Scholar
• Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, et al. OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis 2011; 2:e221; http://dx.doi.org/10.1038/cddis.2011.104; PMID: 22012255
   PubMed Web of Science ®Google Scholar
• Liu QH, Zhao CY, Zhang J, Chen Y, Gao L, Ni CY, Zhu MH. Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: comparative proteomic analyses. Mol Med Rep 2012; 6:767 - 73; PMID: 22858734
   PubMed Web of Science ®Google Scholar
• Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair 2012; 5:7; http://dx.doi.org/10.1186/1755-1536-5-7; PMID: 22564335
   PubMedGoogle Scholar
• Schäfer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, Ziesch A, Palagyi A, Ochs S, Laubender RP, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med 2012; 16:1776 - 91; http://dx.doi.org/10.1111/j.1582-4934.2011.01473.x; PMID: 22004109
   PubMed Web of Science ®Google Scholar
• Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Maehara S, Maehara Y, Sakaida I, Nakamura K. Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells. Anticancer Res 2010; 30:2539 - 43; PMID: 20682980
   PubMed Web of Science ®Google Scholar
• Nakashima M, Adachi S, Yasuda I, Yamauchi T, Kawaguchi J, Itani M, Yoshioka T, Matsushima-Nishiwaki R, Hirose Y, Kozawa O, et al. Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells. Cancer Lett 2011; 313:218 - 25; http://dx.doi.org/10.1016/j.canlet.2011.09.008; PMID: 21999932
   PubMed Web of Science ®Google Scholar
• Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB. MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 2005; 17:37 - 48; http://dx.doi.org/10.1016/j.molcel.2004.11.021; PMID: 15629715
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099 - 109; http://dx.doi.org/10.1158/0008-5472.CAN-04-1443; PMID: 15466206
   PubMed Web of Science ®Google Scholar
• Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG. Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br J Haematol 2011; 152:401 - 12; http://dx.doi.org/10.1111/j.1365-2141.2010.08526.x; PMID: 21689083
   PubMed Web of Science ®Google Scholar
• Ibrahim N, Yu Y, Walsh WR, Yang JL. Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). [review] Oncol Rep 2012; 27:1303 - 11; PMID: 22323095
   PubMed Web of Science ®Google Scholar